Oricell Therapeutics Raises $110M in Pre-IPO Financing

Why It Matters

The capital boost accelerates Oricell’s clinical progression, potentially expanding CAR‑T beyond hematologic cancers and attracting global biotech interest in China’s solid‑tumor immunotherapy sector.

Key Takeaways

• $40M new funding pushes total to $110M.
• Focus on GPC3‑targeted CAR‑T for liver cancer.
• Pre‑IPO round aims for listing within 18 months.
• Backed by Chinese venture and strategic biotech investors.
• Positions Oricell among few Chinese solid‑tumor CAR‑T developers.

Pulse Analysis

CAR‑T therapy has reshaped oncology, yet its success has been largely confined to blood cancers. Investors and regulators are now eyeing solid‑tumor applications, a market projected to exceed $10 billion by 2030. China’s biotech ecosystem, bolstered by government incentives and a growing talent pool, is rapidly scaling to meet this demand, positioning domestic firms to compete with Western incumbents.

Oricell Therapeutics leveraged a fresh $40 million injection to lift its total financing above $110 million. The round, described as pre‑IPO financing, was led by a consortium of Chinese venture capital firms and strategic biotech partners. Proceeds will fund the next‑stage IND‑enabling studies for its GPC3‑targeted autologous CAR‑T candidate, aimed at hepatocellular carcinoma, and advance parallel pipelines addressing other solid‑tumor antigens. By securing domestic capital, Oricell reduces reliance on foreign funding, preserving IP control and aligning with national biotech priorities.

Looking ahead, Oricell’s plan to list within 12‑18 months signals confidence in both its pipeline and the broader market appetite for innovative immunotherapies. An IPO would provide liquidity for early investors and broaden the company’s access to public‑market resources, essential for costly clinical trials. As few Chinese companies have reached late‑stage development of solid‑tumor CAR‑T, Oricell’s progress could catalyze further investment in the sector, reshaping the competitive landscape and accelerating patient access to next‑generation cancer treatments.

Deal Summary

Oricell Therapeutics, a China-based developer of CAR‑T therapies for solid tumors, announced it has raised over $110 million in a pre‑IPO financing round. The capital will fund the advancement of its GPC3‑targeted autologous CAR‑T program and support the company's planned public listing. The round underscores strong investor interest in the biotech's pipeline.